Published in Blood on December 17, 2009
Microvesicles as mediators of intercellular communication in cancer--the emerging science of cellular 'debris'. Semin Immunopathol (2011) 2.78
Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev (2012) 2.22
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol (2013) 1.39
Targeting stroma to treat cancers. Semin Cancer Biol (2011) 1.33
Axl-dependent signalling: a clinical update. Clin Sci (Lond) (2012) 1.28
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am (2013) 1.22
Oncogenic extracellular vesicles in brain tumor progression. Front Physiol (2012) 1.15
Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. Front Immunol (2014) 1.10
Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol (2013) 1.09
Axl as a mediator of cellular growth and survival. Oncotarget (2014) 0.99
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta (2015) 0.98
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clin Cancer Res (2015) 0.96
Relationship between circulating and tissue microRNAs in a murine model of breast cancer. PLoS One (2012) 0.96
Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood (2015) 0.95
Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine (2015) 0.92
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy. Cancer Biol Ther (2013) 0.91
Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed) (2012) 0.91
Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol (2010) 0.90
Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut (2015) 0.90
Microvesicles secreted from human multiple myeloma cells promote angiogenesis. Acta Pharmacol Sin (2013) 0.89
Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. Genes Immun (2011) 0.89
The emerging roles of tumor-derived exosomes in hematological malignancies. Leukemia (2017) 0.87
Small but mighty: microparticles as mediators of tumor progression. Cancer Microenviron (2014) 0.86
Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring. Mol Clin Oncol (2015) 0.86
Transfer of microRNAs by extracellular membrane microvesicles: a nascent crosstalk model in tumor pathogenesis, especially tumor cell-microenvironment interactions. J Hematol Oncol (2015) 0.84
Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget (2014) 0.84
Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia. Blood (2011) 0.84
Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia. PLoS One (2014) 0.83
Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. J Extracell Vesicles (2016) 0.82
Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia (2014) 0.82
Critical signal transduction pathways in CLL. Adv Exp Med Biol (2013) 0.81
Role of Extracellular Vesicles in Hematological Malignancies. Biomed Res Int (2015) 0.81
Predictive prognostic role of miR-181a with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients. Biomed Rep (2014) 0.81
Extracellular vesicles in hematological disorders. Rambam Maimonides Med J (2014) 0.81
CLL Exosomes Modulate the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively Enriched in miR-202-3p. PLoS One (2015) 0.80
Avian leukosis virus subgroup J induces VEGF expression via NF-κB/PI3K-dependent IL-6 production. Oncotarget (2016) 0.79
MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. Oncotarget (2016) 0.79
Glioblastoma microvesicles promote endothelial cell proliferation through Akt/beta-catenin pathway. Int J Clin Exp Pathol (2014) 0.78
Avoiding false positive antigen detection by flow cytometry on blood cell derived microparticles: the importance of an appropriate negative control. PLoS One (2015) 0.78
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget (2015) 0.77
Dynamic probabilistic threshold networks to infer signaling pathways from time-course perturbation data. BMC Bioinformatics (2014) 0.77
VEGF and bFGF gene polymorphisms in Polish patients with B-CLL. Med Oncol (2013) 0.77
Dynamic regulation of CD24 expression and release of CD24-containing microvesicles in immature B cells in response to CD24 engagement. Immunology (2015) 0.77
Cancer stem cells and exosome signaling. Stem Cell Investig (2015) 0.76
Extracellular Vesicles in Brain Tumor Progression. Cell Mol Neurobiol (2016) 0.76
Microvesicles as a potential biomarker of neoplastic diseases and their role in development and progression of neoplasm. Prz Menopauzalny (2015) 0.76
Impact of collection, isolation and storage methodology of circulating microvesicles on flow cytometric analysis. Exp Ther Med (2015) 0.76
Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. Oncotarget (2016) 0.76
The emerging roles of exosomes in tumor-stroma interaction. J Cancer Res Clin Oncol (2016) 0.76
Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells. Front Pharmacol (2017) 0.75
Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget (2016) 0.75
Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer. Pancreas (2016) 0.75
Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: implication in disease progression. Leukemia (2016) 0.75
Saline is a more appropriate solution for microvesicles for flow cytometric analyses. Oncotarget (2017) 0.75
Comparison of microRNA expression profiles in K562-cells-derived microvesicles and parental cells, and analysis of their roles in leukemia. Oncol Lett (2016) 0.75
Vesicle transfer and cell fusion: Emerging concepts of cell-cell communication in the tumor microenvironment. Cancer Biol Ther (2011) 0.75
Liquid crystal droplet-based amplification of microvesicles that are shed by mammalian cells. Analyst (2014) 0.75
The extracellular role of DNA damage repair protein APE1 in regulation of IL-6 expression. Cell Signal (2017) 0.75
Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases. Int Neurourol J (2017) 0.75
TOR signaling in growth and metabolism. Cell (2006) 35.29
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 19.86
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
The renaissance of GSK3. Nat Rev Mol Cell Biol (2001) 7.99
Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol (2008) 7.30
Clinical staging of chronic lymphocytic leukemia. Blood (1975) 7.29
Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia (2006) 6.45
Exosomal-like vesicles are present in human blood plasma. Int Immunol (2005) 6.04
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem (2007) 4.60
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45
Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem (1997) 4.28
The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J (1995) 4.26
Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell (2001) 3.93
Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol (1999) 3.21
Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer (2005) 3.19
Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol (2005) 2.43
Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood (1995) 2.40
Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev (2006) 2.16
Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem (2003) 2.12
VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer (2008) 2.09
AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res (2008) 2.01
Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia (2007) 1.97
Isolation of human platelet membrane microparticles from plasma and serum. Blood (1982) 1.74
Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol (2007) 1.71
Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp Cell Res (2000) 1.67
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell (2004) 1.67
Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem (2002) 1.66
Transfer of differentiation signal by membrane microvesicles harboring hedgehog morphogens. Blood (2006) 1.58
Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett (2008) 1.50
Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia (2000) 1.46
Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol (2008) 1.44
Mechanisms of soluble cytokine receptor generation. J Immunol (2004) 1.44
Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol (2007) 1.44
Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res (2007) 1.41
VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia (2001) 1.37
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood (2002) 1.32
Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood (2009) 1.29
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer (2004) 1.27
Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res (2009) 1.12
Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol (2000) 1.08
Circulating nucleic acids and proteomics of plasma/serum: clinical utility. Ann N Y Acad Sci (2004) 1.03
Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. Cancer Cell (2006) 1.03
Molecular crosstalk between p70S6k and MAPK cell signaling pathways. Biochem Biophys Res Commun (2002) 1.02
Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum Genet (1996) 0.85
International network of cancer genome projects. Nature (2010) 20.35
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol (2003) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet (2005) 2.63
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol (2012) 2.36
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood (2007) 2.31
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol (2008) 2.29
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res (2008) 2.20
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res (2006) 2.12
Nox2 and Rac1 regulate H2O2-dependent recruitment of TRAF6 to endosomal interleukin-1 receptor complexes. Mol Cell Biol (2006) 2.12
Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin Invest (2010) 2.06
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma (2007) 1.92
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood (2010) 1.83
Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model. Kidney Int (2013) 1.83
Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem (2003) 1.82
The use of microorganisms for the formation of metal nanoparticles and their application. Appl Microbiol Biotechnol (2005) 1.81
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood (2010) 1.80
Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene (2003) 1.79
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res (2002) 1.79
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood (2010) 1.79
Antiangiogenic properties of gold nanoparticles. Clin Cancer Res (2005) 1.78
Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol (2002) 1.76
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood (2009) 1.75
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood (2004) 1.73
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.71
Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood (2002) 1.70
Pregnancies and births achieved from in vitro matured oocytes retrieved from poor responders undergoing stimulation in in vitro fertilization cycles. Fertil Steril (2003) 1.67
Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2. J Cell Sci (2007) 1.66
Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest (2003) 1.66
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood (2002) 1.63
Myogenic Akt signaling regulates blood vessel recruitment during myofiber growth. Mol Cell Biol (2002) 1.63
c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology (2011) 1.61
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma (2012) 1.61
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood (2003) 1.60
Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res (2003) 1.60
Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology (2010) 1.60
GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet (2011) 1.58
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
Endothelial cell-specific chemotaxis receptor (ecscr) promotes angioblast migration during vasculogenesis and enhances VEGF receptor sensitivity. Blood (2010) 1.55
New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol (2013) 1.54
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev (2009) 1.54
Electron paramagnetic resonance-guided normobaric hyperoxia treatment protects the brain by maintaining penumbral oxygenation in a rat model of transient focal cerebral ischemia. J Cereb Blood Flow Metab (2006) 1.54
Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol (2009) 1.51
Revealing the role of phospholipase Cβ3 in the regulation of VEGF-induced vascular permeability. Blood (2012) 1.51
C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB J (2006) 1.50
Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer. ACS Chem Biol (2012) 1.50
Concern Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells. PLoS One (2013) 1.49
Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma (2010) 1.49
KDR stimulates endothelial cell migration through heterotrimeric G protein Gq/11-mediated activation of a small GTPase RhoA. J Biol Chem (2002) 1.49
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol (2009) 1.48
NHERF-2 maintains endothelial homeostasis. Blood (2012) 1.47
Oocyte vitrification technology has made egg-sharing donation easier in China. Reprod Biomed Online (2011) 1.45
Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ Res (2008) 1.43
Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res (2008) 1.42
Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis (2013) 1.40
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer (2007) 1.38
Arsenite causes DNA damage in keratinocytes via generation of hydroxyl radicals. Chem Res Toxicol (2004) 1.37
Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnology (2007) 1.37
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell (2005) 1.37
Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J (2005) 1.37
Effect of insulin deprivation on muscle mitochondrial ATP production and gene transcript levels in type 1 diabetic subjects. Diabetes (2007) 1.36
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol (2013) 1.34
Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology (2012) 1.34
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol (2008) 1.33
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol (2009) 1.33
Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells (2009) 1.33
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol (2007) 1.32
Snrk-1 is involved in multiple steps of angioblast development and acts via notch signaling pathway in artery-vein specification in vertebrates. Blood (2008) 1.32
Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PLoS One (2007) 1.32
Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res (2004) 1.31
How we treat Richter syndrome. Blood (2014) 1.31
Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem (2005) 1.31
Adventitial remodeling with increased matrix metalloproteinase-2 activity in a porcine arteriovenous polytetrafluoroethylene grafts. Kidney Int (2005) 1.30
Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol (2006) 1.30
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther (2006) 1.29
Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood (2009) 1.29
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer (2008) 1.29
The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol (2008) 1.29
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer (2010) 1.28